Symeres Acquires DGr Pharma
September 15, 2025
Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.
- Buyers
- Symeres, Keensight Capital
- Targets
- DGr Pharma
- Platforms
- Symeres
- Industry
- Healthcare Services
- Location
- Netherlands
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
May 25, 2021
Healthcare Services
Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.
-
Symeres Acquires Oncolines
January 10, 2023
Healthcare Services
Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.
-
Symeres Acquires Exemplify BioPharma
October 25, 2022
Pharmaceuticals
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
Symeres Acquires Organix Inc.
April 26, 2022
Biotechnology
Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.
-
Syros Pharmaceuticals Merges with TYME Technologies
September 16, 2022
Biotechnology
Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.
-
athagoras Acquires DiaMed Beratungsgesellschaft für pharmazeutische Unternehmen mbH
October 16, 2025
Healthcare Services
athagoras has acquired DiaMed Beratungsgesellschaft für pharmazeutische Unternehmen mbH, a German consultancy specialising in Regulatory Affairs and Pharmacovigilance, to strengthen its RA/PV capabilities and expand local capacity in Germany. The deal adds DiaMed's experienced team to athagoras' European life‑sciences services platform and complements existing operations including CSO Pharma and S-cubed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.